Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Scancell Holdings ( (GB:SCLP) ) has issued an announcement.
Scancell Holdings plc reported strong clinical and organizational progress in its interim results for the six months ending 31 October 2024. The company’s lead cancer vaccine, SCIB1, showed impressive results in advanced melanoma trials, and the next-generation iSCIB1+ and Modi-1 vaccines are advancing well, with promising outcomes in other cancer studies. Strategic partnerships and recent financial activities, including a capital raise of £11.3 million, strengthen Scancell’s position to achieve key clinical milestones in 2025, ensuring continued innovation and development in cancer treatment.
More about Scancell Holdings
Scancell Holdings plc is a clinical stage biopharmaceutical company focused on developing novel immunotherapy products for cancer treatment. Utilizing its proprietary technology platforms, Moditope®, ImmunoBody®, GlyMab®, and AvidiMab®, the company aims to address significant unmet medical needs by generating innovative vaccines and antibodies that target specific protein and lipid modifications.
YTD Price Performance: -10.14%
Average Trading Volume: 1,175,476
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £101.1M
For an in-depth examination of SCLP stock, go to TipRanks’ Stock Analysis page.
